Targeting neuroendocrine prostate cancer: molecular and clinical perspectives
Neuroendocrine prostate carcinoma, either co-present with the local adenocarcinoma disease or as a result of transdifferentiation later in time, was described as one major process of emerging resistance to androgen deprivation therapies, and at the clinical level it is consistent with the developmen...
Main Authors: | Panagiotis J Vlachostergios, Christos N Papandreou |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2015-02-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2015.00006/full |
Similar Items
-
Impact of Neuroendocrine Differentiation (NED) on Enzalutamide and Abiraterone Efficacy in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Retrospective Analysis
by: Giovanni Farinea, et al.
Published: (2024-08-01) -
Mechanisms of castration resistant prostate cancer formation and progression through neuroendocrine differentiation
by: Xueping Ma, et al.
Published: (2021-09-01) -
Focus on the tumor microenvironment: A seedbed for neuroendocrine prostate cancer
by: Hengfeng Zhou, et al.
Published: (2022-07-01) -
A rare primary large-cell neuroendocrine carcinoma of the prostate: A case report
by: Yifeng Li, et al.
Published: (2023-09-01) -
Undesirable Status of Prostate Cancer Cells after Intensive Inhibition of AR Signaling: Post-AR Era of CRPC Treatment
by: Tomoyuki Makino, et al.
Published: (2021-04-01)